PRESS RELEASE published on 02/28/2023 at 14:30, 1 year 7 months ago FDA Grants Orphan Drug Designation to Jaguar Health for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication in the US
PRESS RELEASE published on 02/23/2023 at 14:30, 1 year 7 months ago Jaguar Health Receives Notice of Allowance for U.S. Patent for Lead FDA Approved Drug Crofelemer
PRESS RELEASE published on 02/21/2023 at 14:30, 1 year 7 months ago Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
PRESS RELEASE published on 02/09/2023 at 14:30, 1 year 7 months ago Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
PRESS RELEASE published on 02/08/2023 at 14:30, 1 year 7 months ago Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
PRESS RELEASE published on 02/01/2023 at 15:45, 1 year 7 months ago Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
PRESS RELEASE published on 02/01/2023 at 14:30, 1 year 7 months ago Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling
PRESS RELEASE published on 01/30/2023 at 14:30, 1 year 7 months ago Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
PRESS RELEASE published on 01/27/2023 at 22:15, 1 year 8 months ago Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PRESS RELEASE published on 01/26/2023 at 14:30, 1 year 8 months ago Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
Published on 09/28/2024 at 02:06, 1 day 1 hour ago Global Education Communities Corp. Reports Second Tranche Closing of Non-Brokered Private Placement
Published on 09/28/2024 at 02:00, 1 day 1 hour ago bettermoo(d)’s Moodrink(TM) Featured in Banners of Well-Known Canadian Retailers
Published on 09/28/2024 at 00:10, 1 day 3 hours ago LQWD Technologies Announces Non-Brokered Private Placement Update
Published on 09/28/2024 at 14:01, 13 hours 36 minutes ago Turkiye Garanti Bankasi A.S.: Explanation on Subordinated Debt Securities to Qualified Investors
Published on 09/27/2024 at 22:30, 1 day 5 hours ago DREAM Pivotal Study Data Presented at the International Surgical Sleep Society 2024 Educational Update
Published on 09/27/2024 at 21:56, 1 day 5 hours ago EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
Published on 09/27/2024 at 18:50, 1 day 8 hours ago PETROFAC ANNOUNCES IN-PRINCIPLE AGREEMENT ON FINANCIAL RESTRUCTURE
Published on 09/27/2024 at 18:40, 1 day 8 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 09/27/2024 at 17:45, 1 day 9 hours ago NFL BIOSCIENCES: 2024 FIRST-HALF BUSINESS AND EARNINGS UPDATE
Published on 09/26/2024 at 18:00, 2 days 9 hours ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2024
Published on 09/26/2024 at 18:00, 2 days 9 hours ago GUILLEMOT CORPORATION: 2024 CONSOLIDATED INTERIM RESULTS
Published on 09/26/2024 at 17:47, 2 days 9 hours ago imerys-26-September-2024-information-share-capital-and-voting-rights-as-of-31-August-2024